Strategies to Achieve Better Clinical Outcomes in Type 2 Diabetes and Its Medical Complications
The online educational activity contains video and slides from the Internal Medicine Section‘s COPD Cluster Session held on July 30, 2016 during the National Medical Association’s 2016 Annual Convention and Scientific Assembly in Los Angeles, CA.
This activity was supported in part by educational grants from Merck & Co, Novo Nordisk, and Sanofi
National Medical Association Annual Convention and Scientific Assembly, 2016
Strategies to Achieve Better Clinical Outcomes in Type 2 Diabetes and Its
Diabetes mellitus has an enormous health and social impact and its incidence is rising throughout the world primarily as a result of unhealthy lifestyles. The benefits of aggressive glycemic control on improved microvascular outcomes have been well established for years but data supporting its role in improving macrovascular outcomes is scarce. However, there is now increasing evidence that a particular class of oral antiglycemic agents may provide macrovascular benefits as well. Recent reports show that 30% of individuals with type 2 diabetes remain undiagnosed and a significant number of those diagnosed have glycemia that is poorly controlled. Poor glycemic control and the associated diabetic complications is observed at a higher rate in individuals of color and contributes to health disparities. Advances in our understanding of the clinical management of diabetes and glucose homeostasis has ushered in a new era in the management of diabetes. The National Medical Association Diabetes Seminar will provide health professionals with an up-to-date review of current recommendations regarding screening and treatment strategies for type 2 diabetes. This proposed seminal will emphasize diagnosis and therapeutic approaches to achieve better glycemic control in African Americans and other at-risk patient populations. Additionally, we will address approaches to prevent and treat microvascular and macrovascular complications of diabetes. Finally our goal is to improve disease outcomes by equipping physicians and other health care providers with the latest tools and strategies available to combat diabetes and its complications.
At the conclusion of this educational seminar, participants should be able to:
- Understand who, when and how to screen for type 2 diabetes.
- Understanding the microvascular benefits of glycemic control in the treatment of type 2 diabetes
- Be familiar with cardiovascular implications of recent major clinical studies such as EMPA-REG
- Recognize the role of good glucose control early in the course of diabetes with emphasis on strategies that minimize hypoglycemia.
- Understand the benefits of combination therapy in the treatment of type 2 diabetes.
- Be familiar with the newer formulation of insulin and how to deploy them to achieve better glycemic control in type 2 diabetes
- Understand the role of the primary care physician and internist in the prevention, early detection and referal of the patient with diabetic retinopathy.
- Understand appropriate prevention, screening, treatment and when to refer the patient with diabetic nephropathy, Gastroparesis and Neuropathy.
Disclosures / Acknowledgement of Financial Support
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose any relevant financial relationships. An individual has a relevant financial relationship if he or she (or spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. As an accredited provider balance, independence, objectivity, and scientific rigor must be demonstrated in all educational activities.
The following faculty presenters and planners/managers have stated that they do not have financial relationships or relationships to products or devices with any commercial interests related to the content of this activity during the past 12 months:
Charles U. Gbadouwey, M.D.
Chanda Nicole Holsey, DrPH, MPH
Sam Dagogo-Jack, M.D.
Rhonda Bentley-Lewis, M.D
James W. Reed, M.D.
Ayotunde Dokun, M.D., Ph.D.
Disclosures of Commercial Relationships
The following have listed the entities with whom they have relationships, not necessarily conflicting:
James Gavin, M.D.
Speaker’s Bureau/Consultant: AstraZeneca, Novo Nordisk, BI/Lilly, Janssen Pharmaceutics
Consultant: Novo Nordisk, Merck, BI/Lily
Advisory Boards: Abbott Diabetes Care and Intarcia
Kwame Osei, M.D.
Advisory Boards: Merck & Co., and AztraZeneca